On 20 March 2017, orphan designation (EU/3/17/1856) was granted by the European Commission to AstraZeneca AB, Sweden, for inebilizumab (also known as MEDI-551) for the treatment of neuromyelitis optica spectrum disorders.
The sponsorship was transferred to Quality Regulatory Clinical Ireland Ltd, Ireland, in September 2018.
The sponsorship was transferred Viela Bio B.V., Netherlands in November 2020.
Please note that this product (marketed as Uplizna) was withdrawn from the Union Register of orphan medicinal products by the European Commission in March 2022 at the time of the granting of a marketing authorisation.
Treatment of neuromyelitis optica spectrum disorders
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
More information is available in the orphan medicine assessment report.
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: